Oryzon presents its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston

Our Chief Scientific Officer, Dr. Tamara Maes travels next week to Boston.  She will present the latest advances of our LSD1 program in hematological malignancies at GTC’s 2nd Epigenetics in Drug Discovery conference in the session Drug Discovery in Epigenetics: on May 30-31 at the Hyatt Harborside in Boston, MA.

Dr. Maes' presentation will take place on May 30th at 16:45 pm under the title “Strong and specific LSD1 inhibitors for treatment of hematological malignancies”. Drugs against LSD1 have been shown to be effective in the treatment of acute leukemia. These preclinical findings have been reported by two British independent groups in recent issues of Nature Medicine and Cancer Cell.

The GTC’s 2nd Epigenetics in Drug Discovery conference brings together a mix of leading experts from the industry and academia and will have preeminent speakers as Dr. Craig C Mello, Nobel Laureate, who will talk about RNAi and Immortality.  The Drug Discovery in Epigenetics session will be chaired by Dr Quamrul Hassan, of Novartis Institutes for BioMedical Research, who will give an overview of current trends to modulate Epigenetic Targets. In the same session, Dr. Rab Prinjha Vice President, Head of Epinova Epigenetics DPU (GlaxoSmithKline), Dr. Arthur M. Krieg Chief Executive Officer of RaNA Therapeutics and Dr.Claes Wahlestedt, Dean for Therapeutic Innovation from University of Miami Miller School of Medicine, will also present interesting aspects of the field. Other companies as Genentech and Pfizer will participate in other sessions.

Epigenetics is a hot spot field in the pharmaceutical industry. It is predicted that world revenues for epigenetic therapies and technologies will reach $2.73bn in 2015 and that the overall market will grow with a CAGR of 16% between 2010 and 2015. Therapies will remain the largest source of revenue in the epigenetics market. The deal activity on the field is intense.